Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
AstraZeneca
Medtronic
McKesson
Merck

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,724,343

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,724,343
Title:Peripheral opioid receptor antagonists and uses thereof
Abstract: The present invention provides a compound of formua I: ##STR00001## wherein X.sup.-, R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.
Inventor(s): Bazhina; Nataliya (Tappan, NY), Donato, III; George Joseph (Swarthmore, PA), Fabian; Steven R. (Barnegat, NJ), Lokhnauth; John (Fair Lawn, NJ), Megati; Sreenivasulu (New City, NY), Melucci; Charles (Highland Mills, NY), Ofslager; Christian (Newburgh, NY), Patel; Niketa (Lincoln Park, NJ), Radebaugh; Galen (Chester, NJ), Shah; Syed M. (Delray Beach, FL), Szeliga; Jan (Croton on Hudson, NY), Zhang; Huyi (Garnerville, NY), Zhu; Tianmin (Monroe, NY)
Assignee: Wyeth, LLC (New York, NY)
Application Number:15/276,347
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,724,343
Patent Claims: 1. A composition comprising a unit dosage form of a compound of formula III ##STR00031## wherein the compound of formula III is present at 7% to 75% based on the total weight of the composition; wherein A.sup.- is an anion of a Bronsted acid; wherein the composition comprises a chelating agent comprising calcium EDTA disodium; wherein the composition is substantially free of tungsten; and wherein the composition comprises less than 190 ppm of a compound of formula II ##STR00032## wherein X.sup.- is an anion of a Bronsted acid.

2. The composition of claim 1, wherein the Bronsted acid is selected from the group consisting of a hydrogen halide, a carboxylic acid, a sulfonic acid, a sulfuric acid, and a phosphoric acid.

3. The composition of claim 1, wherein A.sup.- is selected from the group consisting of chloride, bromide, iodide, fluoride, sulfate, bisulfate, tartrate, nitrate, citrate, bitartrate, carbonate, phosphate, malate, maleate, fumarate, sulfonate, methylsulfonate, formate, carboxylate, methylsulfate, trifluoroacetate, and succinate.

4. The composition of claim 3, wherein A.sup.- is bromide.

5. The composition of claim 1, wherein X.sup.- is selected from the group consisting of chloride, bromide, iodide, fluoride, sulfate, bisulfate, tartrate, nitrate, citrate, bitartrate, carbonate, phosphate, malate, maleate, fumarate, sulfonate, methylsulfonate, formate, carboxylate, methylsulfate, trifluoroacetate, and succinate.

6. The composition of claim 5, wherein X.sup.- is bromide.

7. The composition of claim 1, wherein the composition contains tungsten in an amount of less than about 60 parts per billion.

8. The composition of claim 1, wherein the compound of formula III is a compound of formula III-1: ##STR00033## and the compound of formula II is a compound of formula II-1: ##STR00034##

9. The composition of claim 1, wherein the composition is contained within a package that is substantially free of tungsten.

10. The composition of claim 9, wherein the package is selected from the group consisting of: a syringe, a vial and an ampoule.

11. The composition of claim 10, wherein the package is a syringe.

12. The composition of claim 1, wherein the composition is a solid composition.

13. The composition of claim 12, wherein the solid composition is provided in tablet form.

14. The composition of claim 13, wherein the composition comprises 75 mg to 450 mg of the compound of formula III.

15. The composition of claim 13, wherein the composition comprises 150 mg of the compound of formula III.

16. A method for treating a gastrointestinal disorder in a subject comprising administering the composition of claim 1.

17. The method of claim 16, wherein the gastrointestinal disorder is constipation.

18. The method of claim 17, wherein the constipation is opioid-induced.

19. The method of claim 16, wherein the method comprises intravenously administering the composition to the subject.

20. The method of claim 16, wherein the method comprises orally administering the composition to the subject.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
McKinsey
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.